A combination of the TAPSE/sPAP ratio, along with other non-invasive parameters, may improve the assessment of the risk of short-term mortality in patients with PAH at baseline or at follow-up (32−33). The gene discussed is PDZK1IP1; the disease is pulmonary arterial hypertension.